Etienne, Gabriel <br/><br/>
Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy.  [electronic resource] 

 -  Haematologica  Mar 2014 
 - 458-64 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1592-8721 
<br/><br/><label>Standard No.: </label>10.3324/haematol.2013.095158  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--administration & dosage<br/>Benzamides--administration & dosage<br/>Chromosome Aberrations<br/>Female<br/>Follow-Up Studies<br/>Fusion Proteins, bcr-abl--genetics<br/>Humans<br/>Imatinib Mesylate<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Male<br/>Middle Aged<br/>Piperazines--administration & dosage<br/>Protein Kinase Inhibitors--administration & dosage<br/>Pyrimidines--administration & dosage<br/>Treatment Outcome<br/>Young Adult